EMA Opens Registry for Small and Medium Companies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Opens Registry for Small and Medium Companies


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency launched on December 20, 2010, a public registry about small and medium-sized enterprises (SME) that includes information about SME-registered companies. The goal is to facilitate interaction among these types of companies. For now the, website includes details such as company contact information, activities, and number of employees. In March 2011, according to an EMA press release, the registry will also include information about company products, including what’s in the pipeline. To be included in the registry, companies must be based in the European Economic Area and have submitted to the agency an SME declaration per the European Commission Directive 2003/361/EC.

“This initiative is in line with the overall transparency policy of the Agency,” says the EMA release. The idea is to provide more information to the pubic and, in turn, to increase support for the 20 million SMEs located throughout the European Union.

EMA also has a dedicated SME Office, which provides assistance to companies regarding the development and authorization of drug products. For example, the agency offers help with regulatory procedures, translations, fee reductions, exemptions, and deferrals, says the EMA release. There is also a helpful Question and Answer section on the new registry for SMEs needing more information.

See PharmTech related articles:
EMA Publishes New Transparency Policy (ePT)

EMA Criticized over Transparency Rules (ePT)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here